Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04550442 · ClinicalTrials.gov registry record · Phase 1
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
A Phase 1 study of Recurrent Myelodysplastic Syndrome and Refractory Myelodysplastic Syndrome, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT04550442 is a Phase 1 study of Recurrent Myelodysplastic Syndrome and Refractory Myelodysplastic Syndrome that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 34 participants, below the 53-participant average among 19 other Recurrent Myelodysplastic Syndrome trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04550442, a Phase 1 study of Recurrent Myelodysplastic Syndrome and Refractory Myelodysplastic Syndrome, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial investigates the side effects and best dose of venetoclax when given together with azacitidine and to see how well it works in treating patients with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back (relapsed) or has not responded to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine together may help to control myelodysplastic syndrome or chronic myelomonocytic leukemia.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-09-04 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04550442
The ClinicalTrials.gov registry entry for NCT04550442 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 53-participant average among 19 other Recurrent Myelodysplastic Syndrome trials with a reported enrollment target (36% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Myelodysplastic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT04550442 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04550442 about?
NCT04550442 is a clinical study titled "Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia". This phase I/II trial investigates the side effects and best dose of venetoclax when given together with azacitidine and to see how well it works in treating patients with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back (relapsed) or has not responded to trea...
What is the current status of trial NCT04550442?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2020-09-04. Estimated completion is 2026-03-31.
What conditions does trial NCT04550442 study?
This clinical trial studies the following conditions: Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Therapy-Related Myelodysplastic Syndrome.
What interventions are being tested in trial NCT04550442?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG).
Who is sponsoring clinical trial NCT04550442?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04550442 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
RECRUITING · Phase 1
-
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
RECRUITING · Phase 1
-
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
RECRUITING · Phase 1
Explore more on PlainTrial
Recurrent Myelodysplastic Syndrome
All registered trials for this condition
Refractory Myelodysplastic Syndrome
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.